Discussion
New trial data show that BW-20805, Argo Biopharma‘s long-acting injection therapy for hereditary angioedema (HAE), continues to substantially reduce swelling attacks among adults with HAE for as long as six months after treatment. These findings come from a larger group of people with HAE taking part in the…